Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

OTHER 1 NIH 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 24 Gastrointestinal 6 CNS 6 Tumor-Agnostic 3 Genitourinary 3 Other hematologic neoplasm 2 Lymphoid 2 Sarcoma 1 Plasma cell 1 Other solid neoplasm 1 Myeloid 1 Gynecologic 1 Classical hematology 1

Conditions

Ovarian Neoplasms 1

Interventions

Paclitaxel 268 Carboplatin 264 Cisplatin 194 Bevacizumab 135 pembrolizumab 99 Surveys and Questionnaires 84 Radiotherapy 77 Cyclophosphamide 75 olaparib 67 Blood Specimen Collection 65 Drug Therapy 62 Hyperthermic Intraperitoneal Chemotherapy 60 Gemcitabine 60 niraparib 56 Topotecan 56 Brachytherapy 54 liposomal doxorubicin 52 Taxes 47 Docetaxel 46 Magnetic Resonance Spectroscopy 43 Letrozole 36 Cytoreduction Surgical Procedures 36 Filgrastim 33 Biopsy 33 Surgical Procedures, Operative 32 durvalumab 31 Specimen Handling 31 Doxorubicin 31 Nivolumab 30 Albumin-Bound Paclitaxel 28

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × neratinib × Gynecologic × Clear all

NCT04502602 2026-05-11

iNNOVATE

Virginia Commonwealth University

Phase 1 Active not recruiting

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡